Index

ABO antigen system, 134–5, 136–7, 143–4, 161, 329, 341–2
abruptio placentae, 402–3
acute intertwin transfusion, 402, 405
acute lymphoblastic leukemia (ALL), 367–9
acute myeloid leukemia (AML), 369–70
  evaluation of suspected, 368, 370
  Shwachman–Diamond syndrome risk for, 52–3
acute myeloid leukemia of Down Syndrome (ML-DS), 371–2, 374, 375–7
ADA deficiency. *See* adenosine deaminase deficiency
adaptive immunity
  development of, 25, 26, 31–5
  evolution of, 26
  neonatal immaturity of, 63–6
adenosine deaminase (ADA) deficiency, 71, 83, 97, 105–6. *See also* deficiency of adenosine deaminase 2
adrenal hemorrhage, 385
adrenal masses, 383–5
afibrinogenemia, 296, 297
AGM. *See* aorta–gonad–mesonephros region
AIDS. *See* human immunodeficiency virus
AIN. *See* autoimmune neutropenia
AIT. *See* alloimmune thrombocytopenia
ALL. *See* acute lymphoblastic leukemia
allergic transfusion reactions (ATRs), 346
alloimmune hemolysis, 157. *See also* hemolytic disease of fetus and newborn
alloimmune thrombocytopenia (AIT), 223, 235–6
  clinical presentation of, 228
  diagnosis of, 229–30
    alloantibody testing, 230
    antigen testing, 230
    genotyping, 230
    patient selection for testing, 230
    screening programs, 231
  incidence of, 223
  intracranial hemorrhage in, 228–9, 231, 232, 233–5
  management of, 231, 339–40, 341, 342
    antenatal therapy, 231–2
    efficacy of, 232–3
    future modalities for, 235
    in newborn, 235
    risk stratification and specific strategies for, 233–5
    special considerations, 235
  pathogenesis of, 223
    allo-antibody mediated thrombocytopenia, 227–8
    alloimmunization, 224–7
    human platelet-specific antigens, 223–4, 225, 226
  prognostic factors of, 229
alpha$_2$-antiplasmin deficiency, 301
alpha thalassemia, 169,
  alpha thalassemia trait, 170
  hemoglobin Constant Spring syndromes, 170, 172
  hemoglobin H disease, 170–1
  hemolysis due to, 170–2
  homozygous alpha thalassemia, 3, 170, 171–2
  newborn screening for, 96, 99–101
  silent carrier state, 170
American Academy of Pediatrics, ix
AML. *See* acute myeloid leukemia
amniocentesis
  hemolytic disease of fetus and newborn monitoring with, 140–1
  for homozygous alpha thalassemia, 171–2
amotosalen, 355
amphotericin B, 345
anemia, 113. *See also* congenital anemias; Fanconi anemia; hemolysis
  diagnosis of, 113–15
  erythrocyte transfusions for, 121, 329–30
  fetomaternal unit disorders causing, 117, 401–7
  identification of causes underlying, 115–16
    hemolysis, 117–18
    hemorrhage, 115, 116–17
    hypoproliferative, 118
  physiologic, 6–7, 156, 329–30
  in pregnancy, 414–17
anemia of prematurity (AOP), 120, 126
  historical review of, 6–7
  physiology of, 120
  therapy for
    blood loss minimization, 120–1
    delayed umbilical cord clamping, 121
    erythrocyte transfusions, 121, 329–30
    erythropoietin, 121–4
angiomas, 391
aniline dyes, 175
antibodies. *See also* maternal antibodies
  development of, 33–4
  measurement of function of, 82
  neonatal, 34, 65–6
  normal plasma levels of, 65
antibody deficiency, 67, 68–70
  clinical manifestations of, 74–5
  diagnostic approach to, 82
  management of infants with, 84–5
  management of mothers with, 84–5
  secondary immune disorders associated with, 75
anticoagulant-preservative (AP) solutions, 331–2
anticoagulation therapy, 318–21
anticonvulsants, 413
anti-D antigen immune globulin, 5, 139–40, 141, 146, 341–2
anti-erythrocyte antibodies. *See* maternal antibodies
antigens, 31–2. *See also* blood group antigens
  cluster of differentiation, 18–19, 32–3, 34, 80–1
  human platelet, 223–4, 225, 226, 230
  T-cell recognition of, 33

antiphospholipid antibody syndrome, 411–12
antiretroviral therapy, 79, 426
antithrombin, 315, 319
antithrombin concentrates, for extracorporeal membrane oxygenation, 345
antithrombin III (AT-III), 193
AOP. *See* anemia of prematurity
aorta–gonad–mesonephros region (AGM), 18, 27–8
AP solutions. *See* anticoagulant-preservative solutions
apheresis platelets, 341–2
arterial thromboembolism
  iatrogenic/spontaneous, 315–16, 317–18
  management of, 317–18
  perinatal arterial ischemic stroke, 315, 317–18
asphyxia. *See* perinatal asphyxia
ataxia–telangiectasia (AT), 68–70, 72
AT-III. *See* antithrombin III
ATRs. *See* allergic transfusion reactions
atypical teratoid rhabdoid tumor (ATRT), 388
autoimmune neonatal thrombocytopenia, secondary to maternal immune thrombocytopenic purpura, 213–14
autoimmune neutropenia (AIN), 267, 268
autoimmune syndromes, fetomaternal unit disorders of, 157, 411–12
autologous transfusion, 336–7
AZT. *See* zidovudine

babesiosis, 354
barriers, immune system, 25, 62–3
B-cells, 31–2,
  complement system role in memory of, 31
  deficiencies of, 66–7
    severe combined immunodeficiency disease, 67–71, 80, 81, 83–4, 95, 96–7, 105–6
  development of, 29, 33–4
  evolution of, 26
  flow cytometry enumeration of, 80–1
  innate like atypical, 26–7
  neonatal immaturity of, 63, 64, 65–6
  normal ranges of, 64
Bernard–Soulier syndrome (BSS), 249–50
beta thalassemia, 169
  beta thalassemia trait, 172
  hemoglobin E with, 173
  hemolysis due to, 172–3
  homozygous beta thalassemia, 172–3
  newborn screening for, 96, 98–102
  sickle, 174
betamethasone, 414
BFU-E. *See* erythroid burst-forming unit
bilirubin. *See* hyperbilirubinemia
Bizzozero, Giulio, 10, 1–2
bleeding disorders, 293
  acquired, 301,
    disseminated intravascular coagulation (*See* disseminated intravascular coagulation)
    liver disease, 304–5
    vitamin K deficiency, 301–3
  clinical presentation of, 293–4
  congenital hemorrhagic disorders
    factor deficiencies, 296–301
    familial multiple factor deficiencies, 300
    hemostatic proteins in, 295, 296
    inheritance of, 295–6
  developmental hemostasis and, 293
  laboratory investigations of, 294–5
bleeding time, 461–2
bleeds, fetomaternal, 403
blood cells. *See* hematopoietic cells
blood flow. *See* hemodynamics
blood group antigens, 135–6,
  ABO antigen system, 134–5, 136–7, 143–4, 161, 329, 341–2
  Duffy, 138
  Kell, 137–8, 140
  Kidd, 138–9
  maternal antibodies to, 133, 134–5, 157,
    mechanisms for development of, 134–5, 136
    perinatal communication of, 142–3
    screening of, 139–40, 141, 143, 144
    surveillance of, 140–1
  MNS blood group, 139
  Rhesus, 4, 133, 134–5, 137, 139–41, 143, 144, 146, 329, 341–2
blood islands, 15–16
blood loss. *See also* bleeding disorders
  anemia of prematurity and, 120–1
  anemia testing, 115, 116–17
  fetomaternal unit disorders causing, 117, 401–7
blood pH, blood viscosity and, 188
blood sampling
  delivery and, 452–3
  percutaneous umbilical, 142
  site of, 114, 450–1, 453, 459–60
blood viscosity. *See* hyperviscosity; viscosity
blood volume, in polycythemia, 192
bone marrow. *See also* inherited bone marrow failure syndromes
  biopsy, 272, 463–5
  hematopoiesis in, 16–17, 19, 28–9
  reference intervals, 463–5
"born again spleen," viii
brain
  hemodynamics of, 190
  tumors of, 387–8
BSS. *See* Bernard–Soulier syndrome

cancer. *See also* leukemia; tumor
  inherited bone marrow failure syndrome disposition to, 43–4, 51–3, 55, 56
  maternal, 412–13
  placental metastases, 412–13
  placental tumors, 407
capillaries, blood viscosity and, 188
CAPS. *See* cryopyrin-associated periodic syndromes
carbamazepam, 413
carbon monoxide, elevated levels of, 117–18, 157
carcass blood flow, polycythemia disturbances in, 190
CARD9 deficiency, 282
cardiac failure, hemolytic disease of fetus and newborn and, 144–5
cardiac output, in polycythemia, 188–9
cardiopulmonary blood flow, polycythemia disturbances in, 188–9
cardiopulmonary disorders, polycythemia and, 192–3
carrier testing, 106
cartilage hair hypoplasia (CHH), 68–70, 73
catheter related thromboembolism
  arterial, 315–16, 317–18
  venous, 316, 318
CBC. *See* complete blood count
CBF. *See* cerebral blood-flow
CCSK. *See* clear cell sarcoma of kidney
CD. *See* cluster of differentiation
CDA. *See* congenital dyserythropoietic anemia

cell-mediated immunodeficiency disorders, 66–74
  management of, 83–4
  screening for, 79–80, 81, 95, 96–7, 105–6
central nervous system (CNS) tumors, 387–8
central venous catheter (CVC), 316, 318
cerebral blood-flow (CBF), 190
cerebral sinovenous thrombosis (CSVT), 317, 318
cesarean section, for hemolytic disease of fetus and newborn, 144–5
CFU-C. *See* colony-forming unit in culture
CFU-E. *See* colony-forming unit-erythroid cells
CFU-GM. *See* granulocyte-macrophage colony-forming unit
CFU-Mix. *See* colony forming unit-mix
CFU-S. *See* colony-forming unit in spleen cell
CGD. *See* chronic granulomatous disease
Chédiak–Higashi syndrome (CHS), 68–70, 76, 282–5
chemokines, 34–5
chemotaxis, neutrophil, 280–1
chemotherapy
  for leukemia, 370
  maternal, 412–13
  pharmacokinetic considerations of, 393
CHH. *See* cartilage hair hypoplasia
chorioangioma, 407
choriocarcinoma, 386, 407
choroid plexus tumors, 388
chronic granulomatous disease (CGD), 68–70, 77–8, 82, 285
chronic hyporegenerative neutropenias, 268–70
chronic infantile neurologic cutaneous and articular (CINCA) syndrome, 63, 68–70, 78
chronic intrauterine hypoxia, 212–13
CHS. *See* Chédiak–Higashi syndrome
CID. *See* combined immunodeficiency
CINCA syndrome. *See* chronic infantile neurologic cutaneous and articular syndrome
circulation, embryonic development of, 15–19
circulatory overload, transfusion-associated, 348
clear cell sarcoma of kidney (CCSK), 389
CLP. *See* common lymphoid progenitors
cluster of differentiation (CD) antigens, 18–19, 32–3, 34, 80–1
CMN. *See* congenital mesoblastic nephroma
CMV. *See* cytomegalovirus (CMV)
CNS tumors. *See* central nervous system tumors
coagulation disorders. *See* bleeding disorders
coagulation factors, 295
  deficiencies of, 343
    congenital, 296–301
    familial multiple, 300
    laboratory investigations of, 294–5
  development of, 293, 312
  properties of, 296
  screening tests of, 294, 295
Coats plus, 56
cobalamin deficiency, maternal, 416–17
Cohen syndrome, 49–50, 54
colony forming unit-mix (CFU-Mix), 11, 15
colony-forming unit in culture (CFU-C), 11, 18
colony-forming unit in spleen cell (CFU-S), 10–11
colony-forming unit-erythroid cells (CFU-E), 11, 18–19
colony-stimulating activity (CSA), 11
combined immunodeficiency (CID), 71–4
common lymphoid progenitors (CLP), 28
complement system
  deficiencies of, 67, 78–9
  development of, 31
complete blood count (CBC), 440. *See also* reference intervals
  hereditary spherocytosis diagnosis with, 161
  historical attitudes toward, 453
Cone, Thomas, viii
congenital aleukocytosis, 270
congenital amegakaryocytic thrombocytopenia, 49–50, 248
congenital anemias
  congenital dyserythropoietic anemia, 48–51
  deficiency of adenosine deaminase 2, 48, 49–50
  Diamond–Blackfan anemia, viii, 43, 45–8, 49–50
  genetic variants in, 49–50
  Pearson marrow-pancreas syndrome, 48, 49–50
congenital anomalies, in inherited bone marrow failure syndromes, 43, 45–55
congenital dyserythropoietic anemia (CDA), 48–51
congenital heart disease, thromboembolism in, 316
congenital hemangiomas, 391
congenital mesoblastic nephroma (CMN), 389
congenital neutropenias, 264–5, 290–2,
  Cohen syndrome, 49–50, 54
  cyclic neutropenia, 52, 268–9
  genetic variants in, 49–50, 51, 53–4
  glycogen storage disease type IB, 49–50, 54, 285
  severe congenital neutropenia, 51–2, 268–9
  Shwachman–Diamond syndrome, 43, 45–50, 52–3, 269–70, 288
  WHIM syndrome, 49–50, 54
congenital phagocytic defects, 67, 68–70, 77–8
congenital thrombocytopenias, 54
  Bernard–Soulier syndrome, 249–50
  congenital amegakaryocytic thrombocytopenia, 49–50, 248
  genetic testing for, 253–4
  genetic variants in, 49–50
  gray platelet syndrome, 250
  MYH9-related disease, 250
  thrombocytopenia with absent radii, 43, 45–50, 248–9
  thrombocytopenia with increased risk of leukemia, 249
  thrombocytopenia with radioulnar synostosis, 49–50, 249
  Wiskott–Aldrich syndrome, 49–50, 68–70, 71–2, 76, 245–8, 288–9
congenital viral infections, 417–18,
  cytomegalovirus (CMV), 420–2
  enterovirus, 424
  herpes simplex virus, 423–4
  human immunodeficiency virus, 426–7
  human parvovirus B19, 425–6
  neonatal hemolysis in, 158
  rubella, 422–3
  syphilis, 419–20
  toxoplasmosis, 417–19

corticosteroid therapy, for leukemia, 368–9
corticosteroids, for alloimmune thrombocytopenia, 232–3
cryoprecipitate, 342–4
cryopyrin-associated periodic syndromes (CAPS), 78
CSA. *See* colony-stimulating activity
CSVT. *See* cerebral sinovenous thrombosis
culture, of hematopoietic cells, 11, 13
CVC. *See* central venous catheter
cyanosis, in methemoglobinemia, 176–7
cyclic neutropenia, 52, 268–9
cytarabine, 370, 376–7
cytochrome-b_5 reductase deficiency, 176, 177
cytokines
  development of, 34–5
  neonatal, 30, 33
cytomegalovirus (CMV), 83–4,
  diagnosis of, 421
  in granulocyte transfusions, 344
  hematologic manifestations of, 421–2
  intrauterine, 420–2
  thrombocytopenia and, 215–16
  transfusion transmitted, 332, 352, 353
cytopenia. *See also* anemia; neutropenia; thrombocytopenia
  fetomaternal unit disorder causes of, 401
  in inherited bone marrow failure syndromes, 43, 44

D antigen (RHD), 133, 134–5, 137, 139–41, 143, 144, 146, 341–2
DADA2. *See* deficiency of adenosine deaminase 2
Dam, H., 6
dapsone, 158
Darrow, Ruth, 4
DAT. *See* direct antiglobulin test
DBA. *See* Diamond–Blackfan anemia
DC. *See* dendritic cells; dyskeratosis congenita
deficiency of adenosine deaminase 2 (DADA2), 48, 49–50
definitive erythrocytes, 27
DEHP. *See* 2-(diethylhexyl) phthalate
delayed hemolytic transfusion reactions (DHTRs), 346–7
deletional hemoglobin H, newborn screening for, 96
delivery
  blood sampling and, 452–3
  hemolytic disease of fetus and newborn management at, 143, 144–5
dendritic cells (DC), 33
developmental hemostasis, 293, 312
Dewees, W.P., 2
dexamethasone, 414
DGS. *See* DiGeorge syndrome
DHTRs. *See* delayed hemolytic transfusion reactions
diabetes, maternal, 408
  immunologic changes in, 409
  polycythemia in infants of, 408
  thrombocytopenia in infants of, 409
  thrombosis in infants of, 408–9
Diamond, Louis K., viii, 4–5, 133
Diamond–Blackfan anemia (DBA), viii, 43, 45–8, 49–50
DIC. *See* disseminated intravascular coagulation
2-(diethylhexyl)phthalate (DEHP), 351
DiGeorge syndrome (DGS), 68–70, 72–3, 252
direct antiglobulin test (DAT), 157
direct Coombs test, 157
direct thrombin inhibitors, 413
directed donor transfusions, 335
disseminated intravascular coagulation (DIC)
  as acquired hemorrhagic disorder, 303–4
  in congenital herpes simplex virus infection, 423–4
  in enteroviral infections, 424
  in gestational hypertension, 410–11
  schistocytic hemolytic anemia in, 158
  thrombocytopenia and, 217
DNA repair, Fanconi anemia defect in, 55
DNA sequencing. *See* genetic testing
DOCK8 deficiency, 68–70, 71
donor exposure, 334–5
donor leukocyte effects, in transfusion therapy, 347
Down syndrome, 264
  acute myeloid leukemia of, 371–2, 374, 375–7
  transient myeloproliferative disorder of, 371
    clinical features of, 372–3
    diagnosis and definition of, 374
    differential diagnosis of, 374–5
    hematologic features of, 373–4
    management of, 376–7
    natural history and evolution of, 375–6
    pathogenesis and epidemiology of, 371–2
Duffy antigen system (FY), 138
dyskeratosis congenita (DC), 49–50, 56–7, 68–70, 73, 251

early anemia of prematurity. *See* anemia of prematurity
eclampsia, 409
ECMO. *See* extracorporeal membrane oxygenation
Ehrlich, Paul, 1–2, 10
ELBW infants. *See* extremely low birth weight infants
elliptocytes, 160, 162–3
EMA. *See* eosin-5-maleimide
embryonal tumors, 388
embryonic hematopoiesis, 10
  human studies of, 14, 15–19
  murine studies of, 13–15
  sites of, 28–9
embryonic immune system development, 25, 35, 36
  adaptive system, 25, 26, 31–5
  cells and organs, 28–9
  evolution of immunity and, 25–6
  innate system, 25, 26, 29–31
  origin of fetal hematopoietic stem cells in, 26–8
end tidal carbon monoxide concentration (ETCOc), 117–18
enoxaparin, 319–20
enteral iron supplementation, 125
enterovirus infection, 424
  diagnosis of, 424
  hematologic manifestations of, 424
  thrombocytopenia and, 215–16
  treatment of, 424
enzyme replacement therapy, for adenosine deaminase deficiency, 83, 105–6
eosin-5-maleimide (EMA), 162
eosinopenia, 261–3
eosinophilia, 261–3, 455–9,
  consistent approaches to, 270–1, 272
eosinophilia of prematurity, 262, 455–9
eosinophils
  production of, 261
  reference intervals, 261–2, 455–9
epigenetic changes, in hematopoietic stem cell determination, 27–8
EPO. *See* erythropoietin
erythroblastosis fetalis, 4–5, 133. *See also* hemolytic disease of fetus and newborn
erythroblasts
  in embryonic hematopoiesis, 16–17, 18
  primitive, 16–17

erythrocyte adenosine deaminase, 47
erythrocyte transfusions
  for anemia of prematurity, 121, 329–30
  donor exposure and, 334–5
  dose and administration of, 332–3
  indications for, 329–31
  red blood cell preparations for, 331–2
  risks of, 330
  thresholds for restrictive versus liberal, 331
erythrocytes. *See also* anemia; polycythemia
  antigen systems, 135–6,
    ABO, 134–5, 136–7, 143–4, 161, 329, 341–2
    Duffy, 138
    Kell, 137–8, 140
    Kidd, 138–9
    maternal antibodies to, 133–5, 136, 139–41, 142–3, 144, 157
    MNS blood group, 139
    Rhesus, 4, 133, 134–5, 137, 139–41, 143, 144, 146, 329, 341–2
  blood viscosity and
    concentration effects, 187
    deformity effects, 187
  daily production of, 10
  definitive, 27
  early investigators of, 10
  glucose-6-phosphate dehydrogenase-deficient, 96
  hematopoiesis, 16–17, 18, 28–9
  hereditary enzymopathies of
    glucose-6-phosphate dehydrogenase deficiency, 96, 104–5, 165, 163, 164–7, 413
    other enzyme deficiencies, 168–9
    pyruvate kinase deficiency, 163, 164, 167–9
  hereditary membrane disorders of
    classification of, 159
    hereditary elliptocytosis, 159, 160, 162–3
    hereditary spherocytosis, 159–62, 445, 446
  historical description of, 1–2
  increased destruction of, 3, 156–7
  increased production of, 156
  indices
    history of, 2
    reference intervals, 444–5
  maternal medication effects on, 413
  morphology, 156, 450
  neonatal lifespan of, 155
  primitive, 15, 26–7
  reference intervals
    blood sampling relative to delivery, 452–3
    blood sampling site effects on, 114, 450–1
    erythrocyte count, 443
    erythrocyte indices, 444–5
    erythrocyte morphology, 450
    fragmented red cells, 451
    hematocrit, 113–15, 442–3, 444, 445, 450
    hemoglobin concentration, 113–15, 441, 442, 450
    immature reticulocyte fraction and reticulocyte hemoglobin content, 449, 450
    monocytes, 458–60
    nucleated red blood cells, 449
    red blood cell distribution width, 446–8
    reticulocyte count, 448–9
  sickle, 95
  transfusion preparations of, 331–2
erythroid burst-forming unit (BFU-E), 11
  in embryonic hematopoiesis, 15, 18–19
  kinetics of, 18
erythroids, culture of progenitor cells of, 11
erythropoiesis, iron demand for, 124
erythropoietin (EPO)
  anemia of prematurity therapy with, 121–4
  cost of therapy with, 123
  historical review of, 6–7
  iron status and, 122, 124–6
  neuroprotection by, 123
  physiological functions of, 120
  reference intervals after administration of, 448, 449
  side effects of, 123
  supplemental oxygen effects on, 118
  transfusion therapy and, 335–6
ETCOc. *See* end tidal carbon monoxide concentration
evolution
  of hematopoietic cells, 25–6
  of immunity, 25–6
  of lymphocytes, 26
exchange transfusion, 337
  administration of, 338
  complications of, 338
  component preparation for, 337–8
  glucose-6-phosphate dehydrogenase deficiency and, 167
  for hemolytic disease of fetus and newborn, 4–5, 144–6, 337
  indications for, 337
  partial, 195, 338–9
extracorporeal membrane oxygenation (ECMO), 345
extremely low birth weight (ELBW) infants
  erythrocyte transfusions for, 329–30, 331
  transfusion practices for, 335–6

FA. *See* Fanconi anemia
factor IX deficiency, 296, 297
factor V deficiency, 296, 298
factor V Leiden (FVL), 313–14
factor VII deficiency, 296, 298
factor VIIa, recombinant, 298, 302, 303, 305
factor VIII deficiency, 296–7
factor X deficiency, 296, 299
factor XI deficiency, 296, 300
factor XIII deficiency, 296, 300
familial hemophagocytic lymphohistiocytosis (F-HLH), 68–70, 76, 392
familial platelet disorder with associated myeloid malignancy, 49–50
Fanconi anemia (FA), 54–6,
  congenital anomalies in, 43, 45–55
  genetic variants in, 43–4, 49–50, 55
  thrombocytopenia associated with, 251
favism, 165, 166
febrile nonhemolytic transfusion reactions (FNHTRs), 346
ferritin, plasma levels of, 124
ferritin index, 124
fetal blood flow, polycythemia disturbances in, 190
fetal development
  infection during, 25
  origin of hematopoietic stem cells in, 26–8
fetal growth restriction (FGR), fetomaternal unit disorders causing, 407
fetal hemoglobin (HbF), 3, 95, 98–102, 169
fetal hydrops. *See* hydrops fetalis
fetal hypoxia, polycythemia and, 191, 195
fetal transfusions, 5, 141–2, 232, 339–40
fetomaternal hemorrhage (FMH), 117, 401–2, 403

diagnosis of, 403
management of, 403
maternal anti-erythrocyte antibody development via, 134
outcomes of, 403
fetomaternal unit disorders, 401
abruptio placentae and placenta previa, 402–3
anemia causes in, 117, 401–7
autoimmune syndromes, 157, 411–12
fetal growth restriction in, 407
gestational hypertension, 265–6, 409–11
intrauterine infection, 158, 417–27
maternal diabetes, 408–9
maternal malignancy, 412–13
maternal medications, 158, 217–18, 413–14
maternal nutritional deficiencies, 414–17
neutropenia causes in, 402
thrombocytopenia causes in, 401
twin–twin transfusion syndrome, 265–6, 402, 404–7
FFP. *See* fresh frozen plasma
FGR. *See* fetal growth restriction
F-HLH. *See* familial hemophagocytic lymphohistiocytosis
fibrinogen, 188
fibrinogen deficiency, 296, 297
fibrinolytic system, development of, 293, 312
fibroblastic-myofibroblastic tumors, 386–7
fibromatosis, 386–7
flow cytometry, lymphocyte enumeration using, 80–1
FMH. *See* fetomaternal hemorrhage
FNHTRs. *See* febrile nonhemolytic transfusion reactions
folate deficiency, maternal, 415–16
folic acid, for hereditary spherocytosis, 162
fragmented red cells (FRC), 451
fresh frozen plasma (FFP), 342–4
functional asplenia, viii
FVL. *See* factor V Leiden
FY. *See* Duffy antigen system

G6PD deficiency. *See* glucose-6-phosphate dehydrogenase deficiency
Galen, 1
gamma-beta-delta thalassemia, 173
gammaglobulin
for antibody deficiency, 84–5
for enteroviral infections, 424
gastrointestinal barrier defense, 62–3
gastrointestinal blood flow, 189
gastrointestinal disorders, 193
GATA1 gene, 371–2, 374
G-CSF. *See* granulocyte colony stimulating factor
GCT. *See* germ cell tumors
gemtuzumab ozogamicin, for leukemia, 370
gene therapy, for severe combined immunodeficiency disease, 83, 105–6
genetic counseling
for homozygous alpha thalassemia, 171–2
for inherited bone marrow failure syndromes, 44–7
genetic screening. *See* newborn screening
genetic testing
for alloimmune thrombocytopenia, 230
for congenital thrombocytopenias, 253–4
in Diamond–Blackfan anemia, 47
for immunodeficiency disorders, 82–3
for juvenile myelomonocytic leukemia, 371
germ cell tumors (GCT), 385–6
gestational diabetes, 408
gestational hypertension (GH), 402, 409
neutropenia in infants of, 409–10
polycythemia in infants of, 411
thrombocytopenia in infants of, 410–11
transient hyporegenerative neutropenia and, 265–6
GFR. *See* glomerular filtration rate
GH. *See* gestational hypertension
Gilbert syndrome, 96, 162, 167
Glanzmann thrombasthenia (GT), 253
gliomas, 388
glomerular filtration rate (GFR), polycythemia and, 189–90, 193
glucocorticoids, for Diamond–Blackfan anemia, 47–8
glucose-6-phosphatase deficiency. *See* glycogen storage disease type IB
glucose-6-phosphate dehydrogenase (G6PD) deficiency, 413
hemolysis due to, 163, 164–7
historical studies of, 3
newborn screening for, 96, 104–5, 166
glucose phosphate isomerase (GPI) deficiency, 168
glutathione (GSH), 164
glycogen storage disease type IB (GSD1B), 49–50, 54, 285
GM-CSF. *See* granulocyte-macrophage colony-stimulating factor
GPI deficiency. *See* glucose phosphate isomerase deficiency
graft versus host disease (GVHD), 83, 335, 348
granule deficiency, neutrophil-specific, 288
granulocyte colony stimulating factor (G-CSF), 36, 279
for cyclic neutropenia, 52
for functional phagocyte disorders, 281–2
neutropenia management with, 266, 267, 270
consistent approach to, 271
in gestational hypertension, 410
for sepsis, 344
for severe congenital neutropenia, 51–2
granulocyte transfusions, 272–3, 344–5
granulocyte-macrophage colony-forming unit (CFU-GM), 11, 279
in embryonic hematopoiesis, 15, 18
kinetics of, 18
granulocyte-macrophage colony-stimulating factor (GM-CSF), 36, 279
for functional phagocyte disorders, 281–2
for sepsis, 344
granulocytes. *See also* neutrophils
culture of, 11
defects in, 67, 68–70, 77–8
in embryonic hematopoiesis, 15, 16–17
granulopoiesis, 279
gray platelet syndrome, 250
Gricelli syndrome type 2 (GS2), 68–70, 76
growth factors, hematopoietic, 34–5, 36
GS2. *See* Gricelli syndrome type 2
GSD1B. *See* glycogen storage disease type IB
GSH. *See* glutathione
GT. *See* Glanzmann thrombasthenia
gut-associated lymphatic tissue, 29
GVHD. *See* graft versus host disease

haptoglobin, 157
Hb. *See* hemoglobin
Hb Bart. *See* hemoglobin Bart
Hb CS. *See* hemoglobin Constant Spring
Hb E. *See* hemoglobin E
HbF. *See* fetal hemoglobin
HbH. *See* hemoglobin H
HbS. *See* sickle hemoglobin
HBV. *See* hepatitis B
HCV. *See* hepatitis C
HDFN. *See* hemolytic disease of fetus and newborn
HDW. *See* hemoglobin distribution width
HE. *See* hereditary elliptocytosis
heart disease, congenital, thromboembolism in, 316
HELLP syndrome, 409
helper T-cells, 34–5
hemangioblast, 13–14
hemangioma thrombocytopenia syndrome, 217
hemangiomas, 391
hemangiopericytoma (HPC), 387
hematocrit
  blood viscosity relationship with, 187
  history of, 2, 442
  perinatal factors influencing, 186
  polycythemia and hyperviscosity values, 185–6
  reference intervals, 113–15, 442–3, 444, 445, 450
hematology, historical review of, 1–4, 7
  erythroblastosis fetalis, 4–5
  hemorrhagic disease of newborn, 5–6
  physiologic anemia of infancy and anemia of prematurity, 6–7
hematopoiesis, 10
  early blood cell investigators of, 10
  embryonic, 14, 10, 13–19
  fetal sites of, 28–9
  fetal waves of, 26–8
  hematopoietic stem cell and progenitor cell identification methods for, 10–12
  stem cell model of, 12–13
hematopoietic cells. *See also specific cells*
  culture of, 11, 13
  evolution of, 25–6
  historical descriptions of, 1–2
  historical quantification of, 2
  progenitors of, 10–13
hematopoietic stem cell transplantation (HSCT)
  for leukemia, 368–9, 370, 371
  for severe combined immunodeficiency disease, 67–70, 105–6
hematopoietic stem cells (HSCs)
  development of, 29
  in embryonic hematopoiesis, 14, 10, 13–19
  fetal sites of, 28–9
  human embryonic stem cells, 19
  identification methods for, 10–12
  origin of fetal, 26–8
  site of origin of, 14
hemocytoblasts, 16–17
hemodynamics, 188
  brain, 190
  carcass, 190
  cardiopulmonary, 188–9
  fetal, 190
  gastrointestinal, 189
  renal, 189–90
hemoglobin (Hb)
  concentration
    changes after birth, 6–7, 98–102, 113, 114–15, 156, 442
    erythrocyte transfusions and, 329–30
    reference intervals, 113–15, 441, 442, 450
  developmental changes in, 169
  fetal, 3, 95, 98–102, 169
  historical quantification of, 2
  historical studies of, 3
  in reticulocytes, 449, 450
hemoglobin Bart (Hb Bart), 95–6, 98–102, 169, 169–2
hemoglobin Constant Spring (Hb CS), 170–1, 172
hemoglobin distribution width (HDW), 446–8
hemoglobin E (Hb E), beta thalassemia with, 173
hemoglobin F, in Diamond–Blackfan anemia, 47
hemoglobin F-Poole, 175
hemoglobin H (HbH), 95–6, 99–101, 169, 169
hemoglobin H (HbH) disease, 170–1
hemoglobin Hasharon, 175
hemoglobin M disorders, 176, 177
hemoglobin Portland, 171
hemoglobin SC disease, 174
hemoglobinopathies
  hemolysis due to, 169
    sickle cell disease, 174–5
    thalassemia syndromes, 169–73
    unstable hemoglobinopathies, 175
  historical studies of, 3
  methemoglobinemia, 175–7
  newborn screening for, 174
  follow-up strategies for non-sickling hemoglobinopathies, 102–4
  follow-up strategies for sickling hemoglobinopathies, 102, 103
  limitations of non-genetic, 98–102
  methods for, 97–8
  results interpretation for, 98, 99–101
  sickle cell disease, 93–5, 98, 99–101, 102, 103
  thalassemia, 95–6, 98–102
hemolysis. *See also* hemolytic disease of fetus and newborn
  acquired hemolytic anemias
  alloimmune hemolysis, 157
  congenital infections, 158
  due to maternal autoimmune disease, 157
  due to maternal drugs, 158
  infantile pyknocytosis, 158–9
  intravenous immunoglobulin administration for, 274
  microangiopathic (schistocytic), 158
  vitamin E deficiency, 158
  adverse transfusion reactions, 346–7
  anemia testing, 117–18
  causes of, 155
  in cytomegalovirus, 422
  hemoglobin abnormalities, 169
  sickle cell disease, 174–5
  thalassemia syndromes, 169–73
  unstable hemoglobinopathies, 175
  hereditary enzyme abnormalities
  glucose-6-phosphate dehydrogenase deficiency, 163, 164–7
  pyruvate kinase deficiency, 163, 164, 167–9
  hereditary red blood cell membrane disorders
  classification of, 159
  hereditary elliptocytosis, 159, 160, 162–3
  hereditary spherocytosis, 159–62, 445, 446
  historical studies of, 3
  hyperbilirubinemia and, 118, 156–7
  laboratory features of, 156–6,
  anemia and increased red blood cell production, 156
  increased red blood cell destruction, 156–7

normal neonatal erythrocyte lifespan and, 155
hemolytic disease of fetus and newborn (HDFN)
ABO mismatch causing, 134–5, 136–7, 143–4, 161, 329, 341–2
clinical management of, 139
delayed anemia, 146
future direction of, 146
in utero therapy, 5, 141–2, 339–40
interpretation of positive maternal antibody screen at delivery, 143, 144
neonate diagnosis, 143–4
perinatal communication, 142–3
postnatal, 4–5, 144–6, 337
prenatal prevention, 139–41
worldwide practices, 146
Duffy mismatch causing, 138
historical review of, 4–5
Kell mismatch causing, 137–8, 140
Kidd mismatch causing, 138–9
maternal anti-erythrocyte antibodies in, 133, 134–5, 157
development of, 134–5, 136
perinatal communication of, 142–3
screening of, 139–40, 141, 143, 144
surveillance of, 140–1
maternal risk factors associated with, 136
MNS blood group mismatch causing, 139
Rhesus mismatch causing, 4, 133, 134–5, 137, 139–41, 143, 144, 146, 329, 341–2
transient hyporegenerative neutropenia and, 265–6
hemophagocytic lymphohistiocytosis (HLH), 68–70, 75–7, 83, 392
hemorrhage
adrenal, 385
anemia testing, 115, 116–17
fetomaternal unit disorders causing, 117, 401–7
intracranial, 340–1
maternal anti-erythrocyte antibody development after, 134
hemorrhagic disease of newborn, historical review of, 5–6
hemorrhagic disorders. *See* bleeding disorders
hemostasis
developmental, 293, 312
maternal medication effects on, 413
hemostatic proteins, 295, 296. *See also* coagulation factors
heparin
for disseminated intravascular coagulation, 304
thromboembolism management with, 318–21
heparin-induced thrombocytopenia (HIT), 217–18, 413
hepatic tumors, 390–1
hepatitis B (HBV), 352
hepatitis C (HCV), 352–3
hepatoblastomas, 390–1
hepatomegaly, in transient myeloproliferative disorder, 372–3, 374–5
hereditary elliptocytosis (HE), 159, 160, 162–3
hereditary persistence of fetal hemoglobin (HPFH), 98–102
hereditary pyropoikilocytosis (HPP), 160, 162–3
hereditary spherocytosis (HS), 159–62, 445, 446
herpes simplex virus (HSV), 423–4
hES cells. *See* human embryonic stem cells
Hewson, William, 1–2
hexokinase deficiency, 168
hexosemonophosphate (HMP) shunt, 163, 164
HHS. *See* Hoyeraal–Hreidarsson syndrome
high proliferative potential-colony-forming cells (HPP-CFCs), 11–12
HIGM. *See* hyper-IgM syndrome
Hippocrates, 1
histiocytic disorders, 391–2
HIT. *See* heparin-induced thrombocytopenia
HIV. *See* human immunodeficiency virus
HLH. *See* hemophagocytic lymphohistiocytosis
HMP shunt. *See* hexosemonophosphate shunt
Hole in the Wall Gang Camp, The, viii
Holt, L. Emmett, 2
Hoyeraal–Hreidarsson syndrome (HHS), 56, 57
HPA. *See* human platelet antigens
HPC. *See* hemangiopericytoma
HPFH. *See* hereditary persistence of fetal hemoglobin
HPP. *See* hereditary pyropoikilocytosis
HPP-CFCs. *See* high proliferative potential-colony-forming cells
HS. *See* hereditary spherocytosis
HSCs. *See* hematopoietic stem cells
HSCT. *See* hematopoietic stem cell transplantation
HSV. *See* herpes simplex virus
human embryonic stem (hES) cells, 19
human immunodeficiency virus (HIV)
hematologic manifestations of, 426
intrauterine infection with, 426–7
management of, 426–7
perinatal infection with, 68–70, 79
thrombocytopenia and, 215–16
transfusion-acquired, 351, 352
human parvovirus B19, 425
diagnosis of, 425
hematologic manifestations of, 425–6
thrombocytopenia and, 215–16
treatment of, 426
human platelet antigens (HPA), 223–4, 225, 226, 230
humors, historical concept of, 1
Hurler's syndrome, viii
hydrops fetalis, 142, 144–5, 339–40,
historical review of, 4–5
homozygous alpha thalassemia, 3, 170, 171–2
newborn screening for, 96, 99–101
in parvovirus B19 infection, 425–6
thrombocytopenia and, 212–13
hyperbilirubinemia
in glucose-6-phosphate dehydrogenase deficiency, 96, 104–5, 165–6, 167
hemolysis and, 118, 156–7
in hemolytic disease of fetus and newborn, 133, 136–7, 141, 142–6, 337
in hereditary spherocytosis, 160–1, 162
in infantile poikilocytosis, 163
in pyruvate kinase deficiency, 167
hyperglycemia, 349
hyper-IgM syndrome (HIGM), 68–70, 75
hyperimmunoglobulin E syndrome, 286
hyperkalemia, transfusion therapy and, 350
hyperleukocytosis
in leukemia, 367–8, 369–70
in transient myeloproliferative disorder, 373–5

hypertension. *See* gestational hypertension
hyperviscosity, 185, 195, *See also* polycythemia
  definition of, 185–6
  etiologies of, 191
hypocalcemia, 193–4, 350
hypofibrinogenemia, 296, 297
hypogammaglobulinemia. *See* antibody deficiency
hypoglycemia, 193, 349
hypoproliferative anemia, 118
hypothermia, 266
hypoxia. *See* fetal hypoxia
hypoxic ischemic encephalopathy, 266

IAT. *See* indirect antiglobulin test
IBMFS. *See* inherited bone marrow failure syndromes
ICH. *See* intracranial hemorrhage
idiopathic neonatal neutropenia, 270
IDM. *See* infants of diabetic mothers
IFN-γ, 30–1
IFS. *See* infantile fibrosarcoma
IG%. *See* immature granulocyte percent
IGH. *See* infants of gestational hypertension
IG/μL blood. *See* immature granulocyte count
IL. *See* interleukins
ILC. *See* innate lymphoid cells
immature granulocyte count (IG/μL blood), 454–5, 458
immature granulocyte percent (IG%), 454–5, 458
immature platelet count, 460–4
immature platelet fraction (IPF)
  reference intervals, 460–4
  thrombocytopenia evaluation with, 205–6
immature reticulocyte fraction (IRF), 449, 450
immune dysregulation diseases, 67, 68–70, 75–7
immune system. *See also* embryonic immune system development
  development of, 25, 35, 36
    adaptive system, 25, 26, 31–5
    cells and organs, 28–9
    evolution of immunity and, 25–6
    innate system, 25, 26, 29–31
    origin of fetal hematopoietic stem cells in, 26–8
  evolution of, 25–6
  neonatal
    development of, 25, 29, 30, 31, 32–3, 34, 35, 36
    immaturity of, 62–6
immune thrombocytopenic purpura (ITP), 213–14, 341
immune-mediated neutropenias, 267–8, 274
immunity, 25–6, *See also* adaptive immunity; innate immunity
immunodeficiency disorders, 62
  acquired, 68–70, 79
  antibody deficiencies, 67, 68–70, 74–5, 82, 84–5
  cell-mediated deficiencies, 66–74
    management of, 83–4
    screening for, 79–80, 81, 95, 96–7, 105–6
  classification of, 65–6, 67, 68–70
  complement deficiency, 67, 78–9
  congenital phagocytic defects, 67, 68–70, 77–8
  diagnostic approach to, 79–83
  immune dysregulation diseases, 67, 68–70, 75–7
  innate immunity defects, 67, 68–70, 78
  management of, 83–5
  newborn screening for
    severe combined immunodeficiency disease, 95, 96–7, 105–6
    T-cell deficiencies, 79–80, 81, 95, 96–7, 105–6
  single gene defects, 82–3
immunoglobulin deficiency. *See* antibody deficiency
immunoglobulins
  measurement of function of, 82
  neonatal, 34, 65–6
  normal plasma levels of, 65
  placental transport of, 136
indirect antiglobulin test (IAT), for maternal anti-erythrocyte antibodies, 140–1
INF. *See* interferons
infantile fibrosarcoma (IFS), 387
infantile hemangiomas, 390, 391
infantile poikilocytosis, 163
infantile pyknocytosis, 158–9
infants of diabetic mothers (IDM), 408
  immunologic changes in, 409
  polycythemia in, 408
  thrombocytopenia in, 409
  thrombosis in, 408–9
infants of gestational hypertension (IGH), 402, 409
  neutropenia in infants of, 409–10
  polycythemia in infants of, 411
  thrombocytopenia in infants of, 410–11
infection. *See also* congenital viral infections; transfusion-transmitted infection
  glucose-6-phosphate dehydrogenase deficiency and, 165
  intravenous immunoglobulin administration for, 273–4
  neonatal, 25, 29, 30, 31, 32–3, 34, 35, 36, 62
  neutropenia in, 265, 266–7, 270
  neutrophilia in, 263
  in sickle cell disease, 174
  thrombocytopenia and, 215–16
inherited bone marrow failure syndromes (IBMFS), 43, 57, *See also specific syndromes*
  approach to evaluation of, 43, 44
    family history, 43–4
    laboratory evaluation, 44
    physical examination, 43, 45
  cancer risk in, 43–4, 51–3, 55, 56
  congenital anomalies in, 43, 45–55
  genetic counseling for, 44–7
  genetic variants in, 49–50
  neutropenia in, 270
  radiographic studies for, 44
inherited thrombocytopenia syndromes. *See also* congenital thrombocytopenias
  approach to, 243–4
    exam findings, 245
    family history, 244–5
    peripheral smear, 244
    subsequent evaluations and care, 245, 246, 247
  genetic testing for, 253–4
  platelet function defects, 253
  thrombocytopenia associated with congenital syndromes, 250–2
  thrombocytopenia associated with von Willebrand factor abnormalities and increased platelet destruction, 252–3
inherited thrombophilia (IT), 313–15
innate immunity
  defects of, 67, 68–70, 78
  development of, 25, 26, 29–31
  evolution of, 26
  neonatal immaturity of, 62–3
innate lymphoid cells (ILC), development of, 31
INTERCEPT® system, 355
interferons (INF), 34–5
interleukins (IL)
  development of, 34–5
  eosinophil production regulation by, 261
  neonatal, 30

International Society of Blood Transfusion (ISBT)
human platelet-specific antigens, 223–4
red blood cell antigen systems, 133, 134–6
intracardiac thromboembolism, 316
intracranial hemorrhage (ICH)
alloimmune thrombocytopenia with, 228–9, 231, 232, 233–5
bleeding disorders with, 293–4
platelet transfusions and, 340–1
intrauterine infections. *See* congenital viral infections
intrauterine transfusion (IUT), 5, 141–2, 232, 339–40
intravenous immunoglobulin (IVIG)
for alloimmune thrombocytopenia, 232–5
for antibody deficiency, 84–5
consistent approach to administration of, 273–4
for enteroviral infections, 424
for functional phagocyte disorders, 282
for hemolytic disease of fetus and newborn, 142, 145, 337
for sepsis, 344
intraventricular hemorrhage (IVH), 293–4
IPEX syndrome, 68–70, 76–7
IPF. *See* immature platelet fraction
IRAK4 deficiency, 286
IRF. *See* immature reticulocyte fraction
iron deficiency anemia, 118, 124, 414–15
iron status
maternal effects on neonatal, 415
of preterm infants, 120
enteral iron supplementation, 125
erythropoietin therapy and, 122, 124–6
long-term, 125–6
measurement of, 124–5
parenteral iron supplementation, 125
perinatal iron acquisition, 124
postnatal iron sources, 125
ISBT. *See* International Society of Blood Transfusion
isoimmune neonatal neutropenia, 267
isoniazid, 413
IT. *See* inherited thrombophilia
ITP. *See* immune thrombocytopenic purpura
IUT. *See* intrauterine transfusion
IVH. *See* intraventricular hemorrhage

IVIG. *See* intravenous immunoglobulin
jaundice
in Down syndrome, 372
in glucose-6-phosphate dehydrogenase deficiency, 165–6, 167
in hereditary spherocytosis, 160–1, 162
in pyruvate kinase deficiency, 167

JK. *See* Kidd antigen system
juvenile myelomonocytic leukemia (JMML), 370–1
juvenile xanthogranuloma (JXG), 392

kaposiform hemangioendothelioma (KHE), 391
Kasabach–Merritt syndrome, 217
Kell antigen system (KEL), 137–8, 140
kernicterus
in glucose-6-phosphate dehydrogenase deficiency, 96, 104–5, 165–6, 167
in hemolytic anemia, 118
in hemolytic disease of fetus and newborn, 133, 145–6
KHE. *See* kaposiform hemangioendothelioma
Kidd antigen system (JK), 138–9
kidney tumors, 388–9
KMT2A gene, 367, 369
Korber, E., 3

lactic dehydrogenase (LDH), 157
LAD. *See* leukocyte adhesion deficiency
Landsteiner, Karl, 4
Langerhans cell histiocytosis (LCH), 392
large for gestational age (LGA)
infants of diabetic mothers, 408
polycythemia and, 191
LCH. *See* Langerhans cell histiocytosis
LDH. *See* lactic dehydrogenase
leiomyosarcoma, 387
leukemia, 367. *See also* transient myeloproliferative disorder
acute lymphoblastic, 367–9
acute myeloid, 52–3, 368, 369–70
of Down syndrome, 371–2, 374, 375–7
evaluation of suspected, 368, 370
juvenile myelomonocytic, 370–1
severe congenital neutropenia risk for, 51–2
thrombocytopenia with increased risk of, 249
leukemoid reactions, 263–4, 414

leukocyte adhesion deficiency (LAD), 68–70, 77, 82, 264, 286–7
leukocyte alloimmunization, in transfusion therapy, 347
leukocytes. *See also* eosinophilia; neutropenia; neutrophilia; *specific leukocytes*
blood viscosity and, 188
daily production of, 10
early investigators of, 10
historical description of, 1–2
in leukemia, 367–8, 369–70
maternal medication effects on, 414
reference intervals
blood sampling site effects on, 453
counts in preterm infants, 454–5, 458
counts in term infants, 453–4
eosinophils, 261–2, 455–9
historical attitudes toward, 453
in transient myeloproliferative disorder, 373–5
leukoreduction
cytomegalovirus prevention and, 353
erythrocyte transfusion preparations, 332
Levine, Philip, 4
LGA. *See* large for gestational age
Liley, A.W., 5
lineage-committed hematopoietic cells, 11–13
lipoprotein a, 315
Lippman, H.S., 2
liver
acquired hemorrhagic disorders with disease of, 304–5
hematopoiesis in, 16–17, 18–19, 28–9
thrombocytopenia in failure of, 218
tumors of, 390–1
LMWH. *See* low molecular weight heparin
long-term culture-initiating cells (LTC-IC), 12
low molecular weight heparin (LMWH), 319–20, 321
LTC-IC. *See* long-term culture-initiating cells
Lucas, W.P., 2, 5–6
lung disease, leukemoid reactions and, 263–4
lung injury, transfusion-related, 347–8
lupus erythematosus, 157, 411
lymph nodes, development of, 29

lymphocytes. *See also* B-cells; T-cells
  evolution of, 26
  flow cytometry enumeration of, 80–1
  hematopoiesis, 16–17, 27, 28–9
  measurement of function of, 81–2
  newborn screening of, 79–80, 81, 95, 96–7, 105–6
  severe combined immunodeficiency disease subsets, 67–71

macrophages
  culture of, 11
  development of, 29–30
  hematopoiesis, 15, 16–17, 18, 26–7, 28–9
macrothrombocytopenia, 252
major histocompatibility complex (MHC), 26, 31–2
  deficiencies of, 68–70, 71
  T-cell recognition of, 32–3
malaria, 354
malignancy. *See* cancer
maternal antibodies
  in alloimmune thrombocytopenia, 223, 227–8, 230
  to blood group antigens, 133, 134–5, 157
    mechanisms for development of, 134–5, 136
    perinatal communication of, 142–3
    screening of, 139–40, 141, 143, 144
    surveillance of, 140–1
  in directed donor transfusions, 335
  neutropenia associated with, 267
maternal disorders. *See also* fetomaternal unit disorders
  antibody deficiencies, 84–5
  immune thrombocytopenic purpura, autoimmune neonatal thrombocytopenia secondary to, 213–14
MCA PSV. *See* middle cerebral artery peak systolic velocity
MCH. *See* mean corpuscular hemoglobin
MCHC. *See* mean corpuscular hemoglobin concentration
MCV. *See* mean corpuscular volume
MDS. *See* myelodysplastic syndrome
mean corpuscular hemoglobin (MCH), 444–5
mean corpuscular hemoglobin concentration (MCHC), 444–5
mean corpuscular volume (MCV)
  changes after birth, 156
  in inherited bone marrow failure syndromes, 44
  reference intervals, 443, 445
mean platelet volume (MPV), 460, 462
medulloblastoma, 388
megakaryocytes (MKs)
  hematopoiesis, 15, 16–17, 26–7
  in platelet production, 210–11
menadione, 302
Mendelian susceptibility to mycobacterial disease (MSMD), 287
mesenchymal hamartoma, 390
mesoderm cells, blood cell differentiation of, 13–15
methemoglobinemia, 175–7
methylene blue, 175, 177
MHC. *See* major histocompatibility complex
microangiopathic anemias, 158
microscope, in history of hematology, 1–2
middle cerebral artery peak systolic velocity (MCA PSV), 140–1
Mirasol® system, 355
MKs. *See* megakaryocytes
ML-DS. *See* acute myeloid leukemia of Down syndrome
MNS antigen system, 139
molecular genetics. *See* genetic testing
monocytes
  development of, 29–30
  neonatal, 30
  reference intervals, 458–60
MPO deficiency. *See* myeloperoxidase deficiency
MPV. *See* mean platelet volume
MSMD. *See* Mendelian susceptibility to mycobacterial disease
mucosa, barrier function of, 62–3
multipotent hematopoietic cells, 11–13
murine studies
  of embryonic hematopoiesis, 13–15
  origin of fetal hematopoietic stem cells in, 26–8
MyD88 deficiency, 286
myeloblasts, in leukemia, 369–70
myelodysplastic syndrome (MDS), Shwachman–Diamond syndrome risk for, 52–3
myeloperoxidase (MPO) deficiency, 287
myeloproliferative disorder of Noonan syndrome (NS/MPD), 370–1
MYH9-related disease, 250
myofibroma, 387
NADH-methemoglobin reductase deficiency, 176, 177
Naiman, Laurie, 4
NAIT. *See* alloimmune thrombocytopenia
natalizumab, 413
natural killer (NK) cells
  development of, 30–1
  disorders of, severe combined immunodeficiency disease, 67–71, 80, 81, 83–4, 95, 96–7, 105–6
  evolution of, 26
  flow cytometry enumeration of, 80–1
  normal ranges of, 64
NBS. *See* newborn screening
necrotizing enterocolitis (NEC)
  neutropenia in, 270
  polycythemia and, 193
  thrombocytopenia and, 216
  transfusion therapy and, 348–9
Nelson, Waldo, viii
NEMO deficiency, 68–70, 73–4, 287–8
neonatal alloimmune thrombocytopenia. *See* alloimmune thrombocytopenia
neonatal immune system
  development of, 25, 29, 30, 31, 32–3, 34, 35, 36
  immaturity of, 62–6
neonatal lupus erythematosus (NLE), 411
neonatal-onset multisystem inflammatory disorder (NOMID), 63, 68–70, 78
Netherton syndrome, 68–70, 73
NETs. *See* neutrophil extracellular traps
neuroblastoma, 383–5
neurologic disorders, polycythemia and, 194–5
neuroprotection, erythropoietin therapy for, 123
neutropenia, 264–5. *See also* congenital neutropenias
  with accelerated neutrophil destruction, 266–8, 270
  chronic hyporegenerative, 268–70
  consistent approach to
    bone marrow biopsy, 272
    granulocyte transfusion, 272–3
    intravenous immunoglobulin administration, 273–4
  consistent approaches to, 270–1
    evaluation, 270, 271
    granulocyte colony stimulating factor administration, 271

definition of, 264
fetomaternal unit disorders causing, 402
in infants of gestational hypertension, 409–10
late-onset, 270
phagocytic disorders with, 77
transient hyporegenerative, 265–6, 270
neutrophil extracellular traps (NETs), 281
neutrophilia, 263–4
neutrophils, 279
accelerated destruction of, 266–8
concentration
blood sampling site effects on, 453
counts in preterm infants, 454–5, 458
counts in term infants, 453–4
historical attitudes toward, 453
development of, 30, 279
function of, 289–90
chemotaxis, 280–1
diapedesis and basement membrane passage, 280
migration and adherence, 280
neutrophil extracellular trap creation, 281
phagocytosis, 281
respiratory burst, 281
therapies for deficiencies in, 281–2
functional disorders of, 290–2
CARD9 deficiency, 282
Chédiak–Higashi syndrome, 68–70, 76, 282–5
chronic granulomatous disease, 68–70, 77–8, 82, 285
glycogen storage disease type IB, 49–50, 54, 285
hyperimmunoglobulin E syndrome, 286
IRAK4 deficiency/MyD88 deficiency, 286
leukocyte adhesion deficiency, 68–70, 77, 82, 264, 286–7
Mendelian susceptibility to mycobacterial disease, 287
myeloperoxidase deficiency, 287
NEMO deficiency, 68–70, 73–4, 287–8
Shwachman–Diamond syndrome, 43, 45–50, 52–3, 269–70, 288
specific granule defect, 288
therapies for, 281–2
Wiskott–Aldrich syndrome, 49–50, 68–70, 71–2, 76, 245–8, 288–9
hematopoiesis, 28–9
neonatal, 30
neutrophil-specific granule deficiency, 288
newborn screening (NBS), 93
blood disorders screened via, 95–6
carrier testing, 106
future directions in, 106–7
for glucose-6-phosphate dehydrogenase deficiency, 96, 104–5, 166
for hemoglobinopathies, 174
follow-up strategies for non-sickling hemoglobinopathies, 102–4
follow-up strategies for sickling hemoglobinopathies, 102, 103
limitations of non-genetic, 98–102
methods for, 97–8
results interpretation for, 98, 99–101
sickle cell disease, 93–5, 98, 99–101, 102, 103
thalassemia, 95–6, 98–102
immunologic disorders with hematologic abnormalities screened via
severe combined immunodeficiency disease, 95, 96–7, 105–6
T-cell deficiencies, 79–80, 81, 95, 96–7, 105–6
United States implementation of, 93–5
Newman, Paul, viii–ix
NIPT. *See* non-invasive prenatal testing
nitrites, 175
nitrous oxide, 175
NK cells. *See* natural killer cells
NLE. *See* neonatal lupus erythematosus
NOD-like receptors (NLRs), 63
NOD/SCID murine model, 12
NOMID. *See* neonatal-onset multisystem inflammatory disorder
non-deletional hemoglobin H, newborn screening for, 96
non-invasive prenatal testing (NIPT), for homozygous alpha thalassemia, 171–2
Noonan syndrome, 252, 370–1
NRBC. *See* nucleated red blood cells
NS/MPD. *See* myeloproliferative disorder of Noonan syndrome
nucleated red blood cells (NRBC), 449
anemia tests, 115, 116–17
changes after birth, 156
nutritional deficiencies, maternal, 414–17
nutritional supplementation, erythropoietin therapy and, 122

Octaplas™, 343
OF. *See* osmotic fragility
Oski, Frank, 4
Osler, William, 1–2
osmotic fragility (OF), 161
oxygenation, polycythemia disturbances in
brain, 190
carcass, 190
cardiopulmonary, 188–9
fetal, 190
gastrointestinal, 189
renal, 189–90

P5′N deficiency. *See* pyrimidine 5′nucleotidase deficiency
PAIS. *See* perinatal arterial ischemic stroke
PALs. *See* peripheral arterial catheters
para-aortic splanchnopleura (PS), differentiated blood cells in, 13–15
parental donor transfusions, 335
parenteral iron supplementation, 125
Paris-Trousseau syndrome (PTS), 251–2
partial exchange transfusion (PET), 195, 338–9
parvovirus B19. *See* human parvovirus B19
pathogen recognition, neonatal immaturity of, 63
pathogen reduction/pathogen inactivation (PR/PI), 354–5
pattern recognition receptors (PRRs), neonatal immaturity of, 63
Pearson, Howard Allen, vii, ix
Pearson marrow-pancreas syndrome, 48, 49–50
Pediatric History Center (American Academy of Pediatrics), ix
penicillin prophylaxis, for sickle cell disease, 94
percutaneous umbilical blood sampling (PUBS), 142
perinatal arterial ischemic stroke (PAIS), 315, 317–18
perinatal asphyxia
polycythemia and, 191, 195
thrombocytopenia and, 214–15
peripheral arterial catheters (PALs), 315–16, 317–18

peripheral blood smear, 1–2
peripheral nerve tumors, 383–5
PET. *See* partial exchange transfusion
Peyer's patches, 29
PFA-100 closure time. *See* platelet function analyzer-100 closure time
PGK deficiency. *See* phosphoglycerate kinase deficiency
pH, blood viscosity and, 188
phagocytes, 26, 279. *See also* macrophages; monocytes; neutrophils
  congenital defects in, 67, 68–70, 77–8
  development of, 29–30, 279
  function of, 289–90
    chemotaxis, 280–1
    diapedesis and basement membrane passage, 280
    migration and adherence, 280
    neutrophil extracellular trap creation, 281
    phagocytosis, 281
    respiratory burst, 281
  functional disorders of, 290–2
    CARD9 deficiency, 282
    Chédiak–Higashi syndrome, 68–70, 76, 282–5
    chronic granulomatous disease, 68–70, 77–8, 82, 285
    glycogen storage disease type IB, 49–50, 54, 285
    hyperimmunoglobulin E syndrome, 286
    IRAK4 deficiency/MyD88 deficiency, 286
    leukocyte adhesion deficiency, 68–70, 77, 82, 264, 286–7
    Mendelian susceptibility to mycobacterial disease, 287
    myeloperoxidase deficiency, 287
    NEMO deficiency, 68–70, 73–4, 287–8
    Shwachman–Diamond syndrome, 43, 45–50, 52–3, 269–70, 288
    specific granule defect, 288
    therapies for, 281–2
    Wiskott–Aldrich syndrome, 49–50, 68–70, 71–2, 76, 245–8, 288–9
  measurement of function of, 82
phagocytosis, neutrophil, 281
phenobarbital, 413
phenytoin, 413
phlebotomy, anemia of prematurity and, 120–1
phosphoglycerate kinase (PGK) deficiency, 168
photochemical activation, 354–5
phototherapy
  in glucose-6-phosphate dehydrogenase deficiency, 165–6, 167
  for hemolytic disease of fetus and newborn, 145
  for hereditary spherocytosis, 162
physiologic anemia of infancy, 156, 329–30
  historical review of, 6–7
PIDDs. *See* primary immune deficiency diseases
PKD. *See* pyruvate kinase deficiency
placenta. *See also* fetomaternal unit disorders
  anemia in disorders of, 401–7
  blood sampling of, 452–3
  fetal growth restriction in disorders of, 407
  hematopoiesis in, 28–9
  immunoglobulin transport across, 136
  perinatal arterial ischemic stroke and, 315, 317–18
placenta previa, 402–3
placental insufficiency, thrombocytopenia and, 212–13
placental metastases, 412–13
placental tumors, 407
plasma
  ferritin levels, 124
  proteins in, 187
plasma transfusions, 342–4
plasmapheresis, for hemolytic disease of fetus and newborn, 142
plasticizers, 351
platelet distribution width, 462
platelet function analyzer (PFA)-100 closure time, 462, 464
platelet transfusions, 340
  for alloimmune thrombocytopenia, 232, 235
  dose and administration of, 342
  indications and transfusion thresholds for, 206–7, 340–1
  intrauterine, 339–40
  preparations for, 341–2
platelets. *See also* thrombocytopenia
  antigens, 223–4, 225, 226, 230
  blood viscosity and, 188
  early investigators of, 10
  function of, 211–12
  historical description of, 1–2
  increased destruction of, 252–3
  inherited function defects of, 253
  production of, 210–11
  daily, 10
reference intervals
  blood sampling site effects on, 459–60
  platelet count and mean platelet volume, 460, 462
  platelet function analyzer-100 closure time, 462, 464
  reticulated platelets, immature platelet fraction, and immature platelet count, 460–4
  template bleeding time, 461–2
thrombocytopenia evaluation measurements of, 205–6
in transient myeloproliferative disorder, 373–4, 377
pluripotent stem cells, 19
poikilocytes, 162–3
poikilocytosis, 160, 162–3
polycythemia, 185, 195
  in asymptomatic newborns, 195
  blood viscosity and, 186
    definition of, 186–7
    factors affecting, 187–8
  definition of, 185–6
  etiologies of, 191
  hemodynamics in, 188
    brain, 190
    carcass, 190
    cardiopulmonary, 188–9
    fetal, 190
    gastrointestinal, 189
    renal, 189–90
  historical studies of, 2
  incidence of, 186
  in infants of diabetic mothers, 408
  in infants of gestational hypertension, 411
  management of, 195, 338–9
  symptoms of, 191–2
    blood volume abnormalities, 192
    cardiopulmonary, 192–3
    gastrointestinal, 193
    hematologic, 193
    hypocalcemia, 193–4
    hypoglycemia, 193
    neurologic, 194–5
    renal, 193
portal circulation, development of, 15–16
portal vein thrombosis (PVT), 317, 318, 319
preeclampsia, 402, 409
pregnancy
  anemia during, 414–17
  chemotherapy and radiation therapy during, 412–13
  diabetes during, 408–9
  hypertension in, 265–6, 409–11
  infection during, 158, 417–27

medication effects during, 158, 217–18, 413–14
nutritional deficiencies during, 414–17
preterm infants
anemia of prematurity in, 120, 126
historical review of, 6–7
physiology of, 120
therapy for, 120–4, 329–30
eosinophilia of, 262, 455–9
erythrocytes in, 445
erythropoietin levels in, 120
exchange transfusion with glucose-6-phosphate dehydrogenase-deficient blood in, 167
hematocrit in, 443, 445
intravenous immunoglobulin use in, 84–5
iron deficiency anemia in, 124
iron status of, 120
enteral iron supplementation, 125
erythropoietin therapy and, 122, 124–6
long-term, 125–6
measurement of, 124–5
parenteral iron supplementation, 125
perinatal iron acquisition, 124
postnatal iron sources, 125
leukocyte counts in, 454–5, 458
reticulocyte count in, 448–9
template bleeding time in, 461–2
vitamin E deficiency in, 158
pretransfusion testing, 329
prilocaine, 176
primary immune deficiency diseases (PIDDs), 65–6, 67, 68–70, *See also specific diseases*
primitive erythroblasts, 16–17, 18
primitive erythrocytes, 15, 26–7
primitive hematopoiesis, 26–7
progenitor cells. *See also specific cells*
B-cell, 33–4
commitment of, 12–13
in embryonic hematopoiesis, 14, 10, 13–19
fetal sites of, 28–9
identification methods for, 10–12
origin of fetal, 26–8
site of origin of, 14
T-cell, 32
protein C deficiency, 314
protein S deficiency, 314–15
prothrombin deficiency, 296, 297–8
prothrombin gene mutations, 314
PR/PI. *See* pathogen reduction/pathogen inactivation
PRRs. *See* pattern recognition receptors
PS. *See* para-aortic splanchnopleura
PTS. *See* Paris-Trousseau syndrome
PUBS. *See* percutaneous umbilical blood sampling
pulmonary hypertension, 264
pulmonary resistance, in polycythemia, 188–9
PVT. *See* portal vein thrombosis
pyknocytosis, 158–9
pyrimidine 5′nucleotidase (P5′N) deficiency, 168–9
pyruvate kinase deficiency (PKD), hemolysis due to, 163, 164, 167–9

Quick, Armand, 5

radiation, studies of hematopoietic effects of, 10–11
radiation therapy
maternal, 412–13
neonatal, 393
radioulnar synostosis with amegakaryocytic thrombocytopenia (RUSAT), 49–50, 249
rasburicase, for leukemia, 368–9
RDW. *See* red blood cell distribution width
recombinant erythropoietin. *See* erythropoietin
recombinant FVIIa, 298, 302, 303, 305
recombinant tissue plasminogen activator (rTPA), 321–2
recommended universal newborn screening panel (RUSP), 93, 94
red blood cell distribution width (RDW), 446–8
red blood cell transfusions. *See* erythrocyte transfusions
red blood cells. *See* erythrocytes
reference intervals, 440
blood sampling for
delivery and, 452–3
site effects on, 114, 450–1, 453, 459–60
bone marrow, 463–5
end tidal carbon monoxide concentration, 117
erythrocytes
blood sampling relative to delivery, 452–3
blood sampling site effects on, 114, 450–1
erythrocyte count, 443
erythrocyte indices, 444–5
erythrocyte morphology, 450
fragmented red cells, 451
hematocrit, 113–15, 442–3, 444, 445, 450
hemoglobin concentration, 113–15, 441, 442, 450
immature reticulocyte fraction and reticulocyte hemoglobin content, 449, 450
monocytes, 458–60
nucleated red blood cells, 449
red blood cell distribution width, 446–8
reticulocyte count, 448–9
leukocytes
blood sampling site effects on, 453
counts in preterm infants, 454–5, 458
counts in term infants, 453–4
eosinophils, 261–2, 455–9
historical attitudes toward, 453
platelets
blood sampling site effects on, 459–60
platelet count and mean platelet volume, 460, 462
platelet function analyzer-100 closure time, 462, 464
reticulated platelets, immature platelet fraction, and immature platelet count, 460–4
template bleeding time, 461–2
regulatory T-cells, 33
renal blood flow, polycythemia disturbances in, 189–90
renal function, polycythemia and, 193
renal tumors, 388–9
renal vein thrombosis (RVT), 316–17, 318, 319
reproductive technology, hemolytic disease of fetus and newborn risk and, 135
respiratory barrier defense, 62–3
respiratory burst, 281
respiratory distress
hemolytic disease of fetus and newborn and, 144–5
transfusion therapy and, 348
RET-He. *See* reticulocyte hemoglobin content
reticular dysgenesis, 270
reticulated platelets, 460–4
reticulocyte count
anemia tests, 115, 116–17
changes after birth, 156
reference intervals, 448–9
reticulocyte hemoglobin content (RET-He), 449, 450
reticulocytosis, hemolysis and, 156–6
retinoblastoma, 389–90
Revesz syndrome (RS), 56, 57
RH. *See* Rhesus antigen system

rhabdoid tumor of kidney (RTK), 389
rhabdomyosarcoma (RMS), 386
RHD. *See* D antigen
Rhesus (Rh) antigen system (RH), 4, 133, 134–5, 137, 139–41, 143, 144, 146, 329, 341–2
riboflavin, 355
rifampicin, 413
RMS. *See* rhabdomyosarcoma
RS. *See* Revesz syndrome
RTK. *See* rhabdoid tumor of kidney
rTPA. *See* recombinant tissue plasminogen activator
rubella, 422–3
RUSAT. *See* radioulnar synostosis with amegakaryocytic thrombocytopenia
RUSP. *See* recommended universal newborn screening panel
RVT. *See* renal vein thrombosis

sacrococcygeal teratoma (SCT), 385
sarcomas, 386–7
SCD. *See* sickle cell disease
schistocytic anemias, 158
SCID. *See* severe combined immunodeficiency disease
SCN. *See* severe congenital neutropenia
Scott, Roland, 3
screening. *See also* newborn screening
  for alloimmune thrombocytopenia, 231
  coagulation tests, 294, 295
  maternal anti-erythrocyte antibodies, 139–40, 141, 143, 144
  pretransfusion, 329
SCT. *See* sacrococcygeal teratoma
SDPs. *See* single-donor platelets
SDS. *See* Shwachman–Diamond syndrome
secondary hemophagocytic lymphohistiocytosis, 76
SEGA. *See* subependymal giant cell astrocytoma
self-recognition, immune system, 26, 32–3
SEPS. *See* subdiaphragmatic extralobar pulmonary sequestration
sepsis
  granulocyte transfusions for, 344–5
  neonatal hemolysis in, 158
  neutropenia of, 265, 266–7, 270
  in sickle cell disease, 174
  thrombocytopenia and, 215–16
severe combined immunodeficiency disease (SCID)
  diagnostic approach to, 80, 81
  lymphocyte subsets, 67–71
  management of, 83–4, 105–6
  newborn screening for, 95, 96–7, 105–6
severe congenital neutropenia (SCN), 51–2, 268–9
SGA. *See* small for gestational age
SHM. *See* somatic hypermutation
Shwachman–Diamond syndrome (SDS), 43, 45–50, 52–3, 269–70, 288
sickle beta thalassemia, 174
sickle cell disease (SCD)
  hemolysis due to, 174–5
  historical studies of, 3
  newborn screening for, 93–5, 98, 99–101, 102, 103
sickle hemoglobin (HbS), 95, 98–102, 174
Sidbury, J.B., 6
silent carrier state, alpha thalassemia, 170
silent transient myeloproliferative disorder, 374
single-donor platelets (SDPs), 341–2
sitosterolemia, 252
skin, barrier function of, 62–3
small for gestational age (SGA)
  infants of diabetic mothers, 408
  polycythemia and, 191–2
Smith, Carl, 3
Smith, Job Lewis, 2
Sn-mesoporphyrin, 167
soft tissue tumors, 386–7
soluble transferrin receptor (sTfR), 124
solvent/detergent-treated plasma, 343
somatic hypermutation (SHM), 31–2
spherocytes, 159–62
spleen, hematopoiesis in, 17, 29
splenectomy, for hereditary spherocytosis, 162
splenic sequestration crisis, 174
splenomegaly, in hereditary spherocytosis, 160–1
stains, 1–2, 10
stem cell model, of hematopoiesis, 12–13
stem cells. *See* hematopoietic stem cells
sTfR. *See* soluble transferrin receptor
stroke, perinatal arterial ischemic, 315, 317–18
subdiaphragmatic extralobar pulmonary sequestration (SEPS), 385
subependymal giant cell astrocytoma (SEGA), 388
supplemental oxygen, anemia with, 118
syphilis, 419
  clinical manifestations of, 419
  diagnosis of, 419–20
  hematologic manifestations of, 420
systemic resistance, in polycythemia, 188–9

T helper cells, 34–5
TACO. *See* transfusion-associated circulatory overload
T-activation, 347
TAGVHD. *See* transfusion-associated graft versus host disease
TAPS. *See* twin anemia polycythemia syndrome
TAR. *See* thrombocytopenia with absent radii
TBD. *See* telomere biology disorder
T-cell receptor (TcR), 32, 63
T-cells, 31–2
  deficiencies of, 66–7, 72–3
    management of, 83–4
    screening for, 79–80, 81, 95, 96–7, 105–6
    severe combined immunodeficiency disease, 67–71, 80, 81, 83–4, 95, 96–7, 105–6
  development of, 29, 32–3
  evolution of, 26
  flow cytometry enumeration of, 80–1
  helper activity of, 34
  measurement of function of, 81–2
  neonatal immaturity of, 63, 64
  normal ranges of, 64
TcR. *See* T-cell receptor
TE. *See* thromboembolism
telomere biology disorder (TBD), 43, 45–57
template bleeding time, 461–2
teratoma, 385, 387
term infants, leukocyte counts in, 453–4
TfR. *See* transferrin receptor
TGF. *See* transforming growth factor
thalassemia
  hemoglobin E with, 173
  hemoglobin S with, 174
  hemolysis due to, 169–73
  historical studies of, 3
  newborn screening for, 95–6, 98–102
therapeutic hypothermia, 266

THI. *See* transient hypogammaglobulinemia of infancy
thrombocytopenia, 201, 207. *See also* alloimmune thrombocytopenia; inherited thrombocytopenia syndromes
  acquired, 210, 218
    asphyxia, 214–15
    autoimmune neonatal thrombocytopenia secondary to maternal immune thrombocytopenic purpura, 213–14
    disseminated intravascular coagulation/malformations, 217
    drug-induced, 217–18
    infection, 215–16
    liver failure, 218
    necrotizing enterocolitis, 216
    placental insufficiency and chronic intrauterine hypoxia, 212–13
    thromboses, 216–17
  classification and evaluation of, 203
    early-onset, 203–4
    late-onset, 204, 205
    platelet production measurements, 205–6
  definition and incidence of, 201–3
  in Down syndrome, 373–4
  fetomaternal unit disorders causing, 401
  heparin-induced, 413
  in infants of diabetic mothers, 409
  in infants of gestational hypertension, 410–11
  intravenous immunoglobulin administration for, 274
  platelet transfusions for, 206–7, 340–1
  polycythemia and, 193
thrombocytopenia with absent radii (TAR), 43, 45–50, 248–9
thrombocytopenia with increased risk of leukemia, 249
thrombocytopenia with radioulnar synostosis, 49–50, 249
thromboembolism (TE), 312, 322
  clinical presentations and locations of, 315
    arterial, 315–16
    venous, 316–17
  in infants of diabetic mothers, 408–9
  management of, 317
    arterial, 317–18
    heparin anticoagulation therapy, 318–21
    thrombolysis, 319, 321–2
    venous, 318, 319
  risk factors for
    clinical, 312–13
    developmental hemostasis and, 312
    inherited thrombophilia, 313–15
  thrombocytopenia and, 216–17
thrombolytic therapy, 319, 321–2
thrombophilia, 313–15
thrombopoietin (Tpo), 210–11
thrombotic thrombocytopenic purpura (TTP), 252–3
thymus
  aplasia or hypoplasia of, 72–3
  development of, 29, 32
  T-cell differentiation in, 32–3
  transplant of, 83
tissue plasminogen activator, 321–2
TLR. *See* toll-like receptor
TMD. *See* transient myeloproliferative disorder
TNF. *See* tumor necrosis factor
toll-like receptor (TLR), 30, 63, 286
toll-like receptor (TLR) 3 deficiency, 68–70, 78
Townsend, C.W., 5
toxemia of pregnancy, 171
toxoplasmosis, 417–19
TPI deficiency. *See* triose phosphate isomerase deficiency
Tpo. *See* thrombopoietin
TRALI. *See* transfusion-related acute lung injury
transferrin receptor (TfR), 124
transforming growth factor (TGF), 34–5
transfusion therapy, 329, 356. *See also* erythrocyte transfusions; exchange transfusion; platelet transfusions
  adverse reactions to, 346
    acute lung injury, 347–8
    allergic, 346
    circulatory overload, 348
    donor leukocyte effects, 347
    febrile nonhemolytic, 346
    graft versus host disease, 335, 348
    hemolytic, 346–7
    metabolic, 349–50
    necrotizing enterocolitis, 348–9
    plasticizer effects, 351
    transfusion-transmitted infection, 332, 351–5
  autologous transfusion, 336–7
  directed donor transfusions, 335
  donor exposure and, 334–5
  extracorporeal membrane oxygenation and, 345
  future directions in, 356
  granulocyte transfusions, 272–3, 344–5
  for hemolytic disease of fetus and newborn, 4–5, 141–2, 144–6, 337, 339–40
  intrauterine, 5, 141–2, 232, 339–40
  irradiated blood components, 341, 348
  maternal anti-erythrocyte antibody development after, 134–5
  plasma and cryoprecipitate transfusions, 342–4
  pretransfusion testing, 329
  recombinant erythropoietin and, 335–6
  whole blood, 333–4
transfusion transmitted cytomegalovirus (TT-CMV), 332, 352, 353
transfusion-associated circulatory overload (TACO), 348
transfusion-associated graft versus host disease (TAGVHD), 335, 348
transfusion-related acute lung injury (TRALI), 347–8
transfusion-related immunomodulation (TRIM), 347
transfusion-transmitted infection, 351–5
  cytomegalovirus, 332, 352, 353
  emerging pathogens, 354
  hepatitis B, 352
  hepatitis C, 352–3
  human immunodeficiency virus, 351, 352
  pathogen reduction/inactivation for prevention of, 354–5
  risks for, 351, 352
  West Nile virus, 352, 353
  Zika virus, 352, 353–4
transient hypogammaglobulinemia of infancy (THI), 74
transient hyporegenerative neutropenias, 265–6, 270
transient myeloproliferative disorder (TMD), of Down syndrome, 371
  clinical features of, 372–3
  diagnosis and definition of, 374
  differential diagnosis of, 374–5
  hematologic features of, 373–4
  management of, 376–7
  natural history and evolution of, 375–6

transient myeloproliferative (cont.)
pathogenesis and epidemiology of, 371–2
transplantable stem cells, sources of, 19
Treponema pallidum, 419–20
TRIM. *See* transfusion-related immunomodulation
triose phosphate isomerase (TPI) deficiency, 168
trisomy 21. *See* Down syndrome
TT-CMV. *See* transfusion transmitted cytomegalovirus
TTP. *See* thrombotic thrombocytopenic purpura
TTTS. *See* twin–twin transfusion syndrome
tufted angioma, 391
tumor, 382, 383, 393
central nervous system, 387–8
epidemiology of, 382, 384
germ cell, 385–6
hepatic, 390–1
histiocytic disorders, 391–2
peripheral nerve tumors and adrenal masses, 383–5
placental, 407
renal, 388–9
retinoblastoma, 389–90
soft tissue, 386–7
treatment of, 393
vascular, 391
tumor necrosis factor (TNF), 34–5
Turner syndrome, 75
22q11 deletion syndrome. *See* DiGeorge syndrome
twin anemia polycythemia syndrome (TAPS), 402, 405
twin–twin transfusion syndrome (TTTS), 402, 404–5
acute intertwin transfusion, 402, 405
clinical manifestations of, 405–6
hematologic outcomes in, 402
neonatal management of, 406–7
transient hyporegenerative neutropenia and, 265–6
twin anemia polycythemia syndrome, 402, 405

UACs. *See* umbilical arterial catheters
UFH. *See* unfractionated heparin
umbilical arterial catheters (UACs), 315–16, 317–18
umbilical blood sampling, 142
umbilical cord, blood loss through, 402–3
umbilical cord clamping, delayed
anemia of prematurity and, 121
autologous transfusion by, 336–7
hematocrit impact of, 186
polycythemia and, 191
unfractionated heparin (UFH), 320–1
United States
hemolytic disease of fetus and newborn in, 139
newborn screening in, 93–5

vaccination, severe combined immunodeficiency disease and, 83–4
van Leeuwenhoek, Antonie, 1–2, 10
vasa previa, 402–3
vascular tumors, 391
venous thromboembolism (VTE), 312
catheter related, 316, 318
cerebral sinovenous thrombosis, 317, 318
intracardiac, 316
management of, 318, 319
portal vein thrombosis, 317, 318, 319
renal vein thrombosis, 316–17, 318, 319
very low birth weight (VLBW) infants
erythrocyte transfusions for, 329–30, 331
leukocyte counts in, 454–5, 458
platelet transfusions for, 340–1
transfusion practices for, 334–7
vessel size, blood viscosity and, 188
viral infection. *See* infection
viscosity, 186
cerebral blood-flow and, 190
definition of, 186–7
factors affecting, 187–8
vitamin B12 deficiency, maternal, 416–17
vitamin E deficiency, 158
vitamin K
deficiency of, 413
as acquired hemorrhagic disorder, 301–3
clinical presentation of, 301
historical review of, 6
in intraventricular hemorrhage, 293–4
laboratory evaluation of, 301–2
treatment of, 302
mechanism of action of, 301
prophylactic administration of, 302–3
sources of, 301
VLBW infants. *See* very low birth weight infants
volume, blood, 192
volume of packed red blood cells. *See* hematocrit
von Gierke disease. *See* glycogen storage disease type IB
von Willebrand factor (vWF) deficiency, 252–3, 296, 298–9
VTE. *See* venous thromboembolism
vWF deficiency. *See* von Willebrand factor deficiency

Waddell, W.W., 6
Wallerstein, Harry, 4–5
warfarin, 413
WAS. *See* Wiskott–Aldrich syndrome
WB transfusions. *See* whole blood transfusions
Weiner, Alexander, 4–5
West Nile virus (WNV), 352, 353
WHIM syndrome, 49–50, 54
Whipple, G.H., 5–6
white blood cells. *See* leukocytes
whole blood (WB) transfusions, 333–4
Wilms tumor, 389
Wintrobe, Maxwell, 1, 2, 3, 442, 444
Wiskott-Aldrich syndrome (WAS), 49–50, 68–70, 71–2, 76, 245–8, 288–9
WNV. *See* West Nile virus
worldwide newborn screening, 94–5
Wright, James Homer, 1–2

xenotransplantation models, 12
XIAP deficiency. *See* x-linked inhibitor of apoptosis deficiency
X-linked agammaglobulinemia (XLA), 68–70, 74
X-linked chronic granulomatous disease, 26
x-linked inhibitor of apoptosis (XIAP) deficiency, 68–70, 76

yolk sac, hematopoiesis in, 13–19, 26–7, 28–9
yolk sac tumor (YST), 386

ZAP70 deficiency, 68–70, 71
zidovudine (AZT), 426
Zika virus (ZIKV), transfusion-acquired, 352, 353–4
zinc protoporphyrin/heme (ZnPP/H) ratios, 125